Table 5 Cardiovascular outcome for 5-flurouracil versus capecitabine
| Â | Cox proportional hazard model | Competing risk Regression | |||||
|---|---|---|---|---|---|---|---|
Variables | Combined N = 6,486 | 5-flurouracil n = 3243 | capecitabine n = 3243 | Hazard Ratio (95% C.I) | P-Value | Hazard Ratio (95% C.I.) | P-Value |
Death | 1,055(16.3%) | 442(13.6%) | 613(18.9%) | 1.35(1.2–1.53) | < 0.001* | - | - |
MACE | 55(0.85%) | 26(0.80%) | 29(0.89%) | 1.09(0.64–1.85) | 0.75 | - | - |
Cardiovascular Death | 25(0.39%) | 14(0.43%) | 11(0.34%) | 0.77(0.35–1.69) | 0.51 | - | - |
Myocardial infarction | 13(0.20%) | 8(0.25%) | 5(0.15%) | 0.61(0.20–1.87) | 0.39 | 0.60(0.20–1.83) | 0.39 |
Ischemic stroke | 35(0.54%) | 12(0.37%) | 23(0.71%) | 1.87(0.93–3.76) | 0.08 | 1.87(0.93–3.76) | 0.08 |
New-onset Atrial fibrillation# | 22/6,394(0.34%)# | 9/3,196(0.28%)# | 13/3,198(0.41%)# | 1.41(0.60–3.30) | 0.43 | 1.40(0.60–3.26) | 0.44 |
Ventricular tachycardia or fibrillation | 3(0.05%) | 1(0.03%) | 2(0.06%) | 1.96(0.18–21.7) | 0.58 | 1.95(0.18–21.2) | 0.58 |